Comments on the 2013 ESC Guidelines on Cardiac Pacing and Cardiac Resynchronization Therapy

Therapy, Cardial Resynchronization; Fernández‐Lozano, Ignacio; Mateas, Francisco Ruíz; Osca, Joaquín; Tello, M.J. Sancho; Bolao, Ignacio García; Ferrer, José Martínez; Andrés, María Luisa Fidalgo; García, Jesús Rodríguez; Therapy, Resynchronization; Ojo, Juan Leal del; Vera, Tomás Ripoll; Sanmartin, R. Coma; Cano, Óscar; Jiménez, Marta Pombo; Palomo, Carmen Medina; Álvarez, Luisa Pérez; Madrid, Antonio Hernández; Castellano, Nicasio Pérez; Girbau, Lluís Mont; Mitjans, Àngel Moya; Arribas, Fernando; Llorens, José Luis Merino; Pérez-Villacastín, Julián; Rodríguez, Javier Alzueta; Salinas, José Ramón Carmona; Fernández‐Ortíz, Antonio; Alonso, Ángel; Anguita, Manuel; Cequier, Ángel; Comín, Josep; Diaz-Buschmann, Isabel; Diego, José Juan Gómez de; Pan, Manuel; Worner, Fernando

doi:10.1016/j.rec.2013.11.002

Cited by 5 publications

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Studies in patients with SND and preserved AV conduction, with randomization for the apical versus the outflow tract of the RV, and that contemplated these aspects, demonstrated the superiority of the latter location in terms of LVEF and remodeling when the follow-up exceeded 18 months [ 63 , 64 ] . Because of the methodological differences for the confirmation of the position of the electrode, however, and because we know that a great part of the hemodynamic results would depend on the obtained diQRS [ 65 ] , until the moment these findings have not been incorporated into the Guidelines.…”

Section: Introductionmentioning

confidence: 99%

“…While the European Guidelines [ 3 ] do not establish a definite value for CVP, the American Guidelines [ 5 ] mention that it must exceed 40% for a recommendation IIa. The American Guidelines also state that despite the absence of symptoms at the time of elective replacement of the conventional PPM generator, when there is reduced LVEF, the upgrade to CRT could be associated with a better outcome [ 65 , 69 , 70 ] .…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Cardiac Pacing Induced Cardiomyopathy: Mith or Reality Sustained by Evidence?

Ferrari¹,

Borges²,

Albuquerque³

et al. 2014

Revista Brasileira De Cirurgia Cardiovascular

View full text Add to dashboard Cite

Implantable cardiac pacing systems are a safe and effective treatment for symptomatic irreversible bradycardia. Under the proper indications, cardiac pacing might bring significant clinical benefit. Evidences from literature state that the action of the artificial pacing system, mainly when the ventricular lead is located at the apex of the right ventricle, produces negative effects to cardiac structure (remodeling, dilatation) and function (dissinchrony). Patients with previously compromised left ventricular function would benefit the least with conventional right ventricle apical pacing, and are exposed to the risk of developing higher incidence of morbidity and mortality for heart failure. However, after almost 6 decades of cardiac pacing, just a reduced portion of patients in general would develop these alterations. In this context, there are not completely clear some issues related to cardiac pacing and the development of this cardiomyopathy. Causality relationships among QRS widening with a left bundle branch block morphology, contractility alterations within the left ventricle, and certain substrates or clinical (previous systolic dysfunction, structural heart disease, time from implant) or electrical conditions (QRS duration, percentage of ventricular stimulation) are still subjecte of debate. This review analyses contemporary data regarding this new entity, and discusses alternatives of how to use cardiac pacing in this context, emphasizing cardiac resynchronization therapy.

show abstract

Section: Introductionmentioning

confidence: 99%